- Home
- TMO
as 06-28-2024 4:00pm EST
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
| Founded: | 1956 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 222.9B | IPO Year: | N/A |
| Target Price: | $604.83 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | 0.28% | Dividend Payout Frequency: | Quarterly |
| EPS: | 15.59 | EPS Growth: | 1.63 |
| 52 Week Low/High: | $415.60 - $603.82 | Next Earning Date: | 07-24-2024 |
| Revenue: | $42,492,000,000 | Revenue Growth: | -3.00% |
| Revenue Growth (this year): | 1.32% | Revenue Growth (next year): | 7.20% |
Stock Insider Trading Activity of Thermo Fisher Scientific Inc (TMO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| CASPER MARC N | TMO | Chairman & CEO | Feb 15 '24 | Sell | $550.29 | 4,447 | $2,447,139.63 | 44,708 | SEC Form 4 |
| CASPER MARC N | TMO | Chairman & CEO | Feb 15 '24 | Sell | $551.75 | 800 | $441,400.00 | 43,908 | SEC Form 4 |
| CASPER MARC N | TMO | Chairman & CEO | Feb 15 '24 | Sell | $552.50 | 300 | $165,750.00 | 43,608 | SEC Form 4 |
| Spar Debora L | TMO | Director | Feb 12 '24 | Sell | $546.97 | 164 | $89,703.08 | 1,207 | SEC Form 4 |
| CASPER MARC N | TMO | Chairman & CEO | Feb 7 '24 | Sell | $552.72 | 1,160 | $641,155.20 | 57,995 | SEC Form 4 |
| CASPER MARC N | TMO | Chairman & CEO | Feb 7 '24 | Sell | $553.83 | 600 | $332,298.00 | 57,395 | SEC Form 4 |
| CASPER MARC N | TMO | Chairman & CEO | Feb 7 '24 | Sell | $554.81 | 3,127 | $1,734,890.87 | 54,268 | SEC Form 4 |
| CASPER MARC N | TMO | Chairman & CEO | Feb 7 '24 | Sell | $555.87 | 3,231 | $1,796,015.97 | 51,037 | SEC Form 4 |
| CASPER MARC N | TMO | Chairman & CEO | Feb 7 '24 | Sell | $556.82 | 900 | $501,138.00 | 50,137 | SEC Form 4 |
| CASPER MARC N | TMO | Chairman & CEO | Feb 7 '24 | Sell | $557.74 | 200 | $111,548.00 | 49,937 | SEC Form 4 |
| CASPER MARC N | TMO | Chairman & CEO | Feb 7 '24 | Sell | $561.03 | 400 | $224,412.00 | 49,537 | SEC Form 4 |
| CASPER MARC N | TMO | Chairman & CEO | Feb 7 '24 | Sell | $562.38 | 382 | $214,829.16 | 49,155 | SEC Form 4 |
Latest Thermo Fisher Scientific Inc News
TMO Breaking Stock News: Dive into TMO Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Does Thermo Fisher Scientific (NYSE:TMO) Have A Healthy Balance Sheet?
Zacks
3 days ago
Thermo Fisher's (TMO) New Launch Speeds Up pDNA Purification
MT Newswires
3 days ago
Barclays Adjusts Price Target on Thermo Fisher Scientific to $600 From $615
Insider Monkey
6 days ago
Thermo-Fisher Scientific Inc. (TMO): Did This Healthcare Stock Exceed Expectations in Q1?
MT Newswires
6 days ago
RBC Trims Price Target on Thermo Fisher Scientific to $660 From $662, Keeps Outperform Rating
Simply Wall St.
7 days ago
Declining Stock and Solid Fundamentals: Is The Market Wrong About Thermo Fisher Scientific Inc. (NYSE:TMO)?
Zacks
10 days ago
Thermo Fisher (TMO) Unveils New Research Laboratory in WI
Zacks
10 days ago
Thermo Fisher's (TMO) New Buyouts Aid Growth, FX Issues Stay
Share on Social Networks:
Disclaimer
The information presented on this page, "TMO Thermo Fisher Scientific Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.